Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Tyme Technologies (TYME)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,027
  • Shares Outstanding, K 111,951
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,980 K
  • 60-Month Beta 0.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.93 +8.60%
on 06/13/19
1.49 -32.12%
on 05/23/19
-0.45 (-30.82%)
since 05/17/19
3-Month
0.93 +8.60%
on 06/13/19
2.34 -56.82%
on 03/20/19
-1.28 (-55.90%)
since 03/19/19
52-Week
0.93 +8.60%
on 06/13/19
4.64 -78.23%
on 12/13/18
-2.71 (-72.85%)
since 06/19/18

Most Recent Stories

More News
TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019

-- SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancers

TYME : 1.01 (-7.34%)
TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)), announced today that it has received notification that the United States...

TYME : 1.01 (-7.34%)
Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)), announced that management will present a corporate overview for 2019...

JNJ : 140.45 (+0.16%)
TYME : 1.01 (-7.34%)
TYME Announces USAN Approval of Generic Name "Racemetyrosine" for SM-88

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs(TM)), announced today that the United States Adopted Name (USAN) Council recently...

TYME : 1.01 (-7.34%)
TYME's SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs

-- SM-88 is an investigational Cancer Metabolism-Based Therapy (CMBTs) that has demonstrated responses across 15 different cancers

TYME : 1.01 (-7.34%)
TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced the closing of its underwritten registered offering with a group...

TYME : 1.01 (-7.34%)
TYME Announces Dismissal of Class Action Lawsuit

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs) announced the consolidated class action complaint filed in the United States...

TYME : 1.01 (-7.34%)
Tyme Technologies Announces Pricing of its $12 Million Registered Offering

Tyme Technologies, Inc. (NASDAQ: TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value $0.0001 per share, and warrants to purchase 8 million...

TYME : 1.01 (-7.34%)
SHAREHOLDER ALERT: VALE TYME UXIN UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request...

TYME : 1.01 (-7.34%)
UMC : 2.13 (+1.91%)
VALE : 13.54 (+0.59%)
UXIN : 2.04 (-1.92%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline - TYME

Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. ("Tyme" or the "Company") (NASDAQ: TYME) and certain of its officers. The class action, filed in United...

TYME : 1.01 (-7.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade TYME with:

Business Summary

Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York.

See More

Key Turning Points

2nd Resistance Point 1.12
1st Resistance Point 1.07
Last Price 1.01
1st Support Level 0.98
2nd Support Level 0.94

See More

52-Week High 4.64
Fibonacci 61.8% 3.22
Fibonacci 50% 2.78
Fibonacci 38.2% 2.35
Last Price 1.01
52-Week Low 0.93

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar